Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 1 / Phase 2	2026-06-04		NCT03960840

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
H Lee Moffitt Cancer Center and Research Institute	Tampa	United States	11
Mass Gen Hosp Cancer Center	Boston	United States	1
Medical College of Wisconsin	Milwaukee	United States	483
Sarah Cannon Research Institute	Nashville	United States	1
St Davids South Austin Medical Ctr	Austin	United States	1
Stanford University Medical Center	Stanford	United States	1
Tennessee Oncology	Nashville	United States	77
Uni of Chi Medi Ctr Hema and Onco	Chicago	United States	5
Uni Of TX MD Anderson Cancer Cntr	Houston	United States	7
University of California LA	Los Angeles	United States	12
University of Kansas Cancer Center	Westwood	United States	36
University of Pennsylvania Clinical	Philadelphia	United States	1